8-KAcquisitions & DispositionsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Acquisition Completed (Aug 10, 2012)

Filed August 10, 2012For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) filed an 8-K on August 9, 2012, primarily to disclose two press releases via its exhibits. These press releases, dated August 8, 2012, and August 9, 2012, are the core of the filing's informational content for investors. Investors should review these press releases for potential material updates regarding the company's business, financial performance, strategic developments, or any other significant corporate events that occurred around the event date of August 7, 2012. The filing itself does not contain direct financial statements or new operational details, but rather points to external documents containing such information. Therefore, a thorough understanding of the company's recent activities and any potential impact on its financial standing requires examining the content of these incorporated press releases. Investors should pay close attention to any announcements related to product pipelines, clinical trials, regulatory approvals, or business combinations detailed within these documents.

Key Highlights

  • 1The 8-K filing's primary purpose is to disclose two press releases as exhibits.
  • 2Press Release dated August 8, 2012, is incorporated by reference from a prior Schedule TO-T/A filing.
  • 3Press Release dated August 9, 2012, is directly included as an exhibit.
  • 4The filing indicates material information is contained within the referenced press releases, not the 8-K itself.
  • 5Investors need to consult the referenced press releases for substantive company updates.
  • 6The filing date is August 9, 2012, with an event date of August 7, 2012.
  • 7Demetrios Kydonieus, Vice President, Strategy, Alliances & Transactions, signed the filing on behalf of the company.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially disclose two press releases issued by Bristol Myers Squibb Company on August 8, 2012, and August 9, 2012. These press releases likely contain material information relevant to investors.

The critical information is contained within the press releases that are attached as exhibits to this 8-K. You will need to access and review Exhibit 99.1 (dated August 8, 2012) and Exhibit 99.2 (dated August 9, 2012) for details.

No, this specific 8-K filing does not include new financial statements. It is categorized under Item 9.01.Financial Statements and Exhibits, and it only lists press releases as exhibits, pointing investors to those documents for financial or operational updates.

The 'Event date' of August 7, 2012, indicates the date on which the specific event(s) or action(s) described in the press releases likely occurred or were decided upon, triggering the need for this disclosure.